{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:09:30Z","timestamp":1758046170462,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ancard.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T16:14:32Z","timestamp":1660148072000},"page":"309-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ce que le cardiologue doit savoir sur le suivi d'un patient pr\u00e9sentant un my\u00e9lome multiple"],"prefix":"10.1016","volume":"71","author":[{"given":"F.","family":"Gilles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ancard.2022.07.001_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ancard.2022.07.001_bib0002","unstructured":"Estimations nationales de l'incidence et de la mortalit\u00e9\u0301 par cancer en France m\u00e9tropolitaine entre 1990 et 2018- Vol. 2: h\u00e9mopathies malignes: \u00e9tude \u00e0 partir des registres des cancers du r\u00e9seau francim. http:\/\/www.santepubliquefrance.fr, publi\u00e9 le 05 juillet 2019, mis \u00e0 jour le 18 septembre 2019."},{"issue":"5","key":"10.1016\/j.ancard.2022.07.001_bib0003","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/ki.1987.131","article-title":"Mechanisms of glucocorticoid-induced hypertension","volume":"31","author":"Whitworth","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.ancard.2022.07.001_bib0004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.ancard.2022.07.001_bib0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(63)91346-1","article-title":"Teratogenic effects of thalidomide and related substances","volume":"1","author":"Boylen","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2022.07.001_bib0006","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit THALIDOMIDE\u00ae. http:\/\/www.ema.europa.eu\/ema\/ , consult\u00e9 le 21 avril 2022."},{"key":"10.1016\/j.ancard.2022.07.001_bib0007","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit REVLIMID\u00ae. http:\/\/www.ema.europa.eu\/ema\/ , consult\u00e9 le 21 avril 2022."},{"key":"10.1016\/j.ancard.2022.07.001_bib0008","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit IMNOVID\u00ae. http:\/\/www.ema.europa.eu\/ema\/ , consult\u00e9 le 21 avril 2022."},{"issue":"4","key":"10.1016\/j.ancard.2022.07.001_bib0009","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ancard.2022.07.001_bib0010","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2022.07.001_bib0011","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.thromres.2008.09.008","article-title":"Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy","volume":"123","author":"Musallam","year":"2009","journal-title":"Thromb Res"},{"issue":"10","key":"10.1016\/j.ancard.2022.07.001_bib0012","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ancard.2022.07.001_bib0013","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit VELCADE\u00ae. http:\/\/www.ema.europa.eu\/ema\/ , consult\u00e9 le 21 avril 2022."},{"key":"10.1016\/j.ancard.2022.07.001_bib0014","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit KYPROLIS\u00ae. http:\/\/www.ema.europa.eu\/ema\/ , consult\u00e9 le 21 avril 2022."},{"key":"10.1016\/j.ancard.2022.07.001_bib0015","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit NINLARO\u00ae. http:\/\/www.ema.europa.eu\/ema\/ , consult\u00e9 le 21 avril 2022."},{"issue":"2","key":"10.1016\/j.ancard.2022.07.001_bib0016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12185-008-0139-7","article-title":"Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib","volume":"88","author":"Hacihanefioglu","year":"2008","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.ancard.2022.07.001_bib0017","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000340050","article-title":"Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature","volume":"128","author":"Bockorny","year":"2012","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.ancard.2022.07.001_bib0018","doi-asserted-by":"crossref","first-page":"e87671","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"Plos One"},{"issue":"2","key":"10.1016\/j.ancard.2022.07.001_bib0019","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24608","article-title":"Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors","volume":"92","author":"Jouni","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ancard.2022.07.001_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ancard.2022.07.001_bib0021","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ancard.2022.07.001_bib0022","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ancard.2022.07.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ancard.2022.07.001_bib0024","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.ancard.2022.07.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the american and european cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.ancard.2022.07.001_bib0026","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ancard.2022.07.001_bib0027","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ancard.2022.07.001_bib0028","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2022.07.001_bib0029","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the esc working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ancard.2022.07.001_bib0030","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V68.1.220.220","article-title":"Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases","volume":"68","author":"Kyle","year":"1986","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ancard.2022.07.001_bib0031","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ancard.2022.07.001_bib0032","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"36","key":"10.1016\/j.ancard.2022.07.001_bib0033","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392822000993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392822000993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:38:29Z","timestamp":1757716709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003392822000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0003392822000993"],"URL":"https:\/\/doi.org\/10.1016\/j.ancard.2022.07.001","relation":{},"ISSN":["0003-3928"],"issn-type":[{"type":"print","value":"0003-3928"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ce que le cardiologue doit savoir sur le suivi d'un patient pr\u00e9sentant un my\u00e9lome multiple","name":"articletitle","label":"Article Title"},{"value":"Annales de Cardiologie et d'Ang\u00e9iologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ancard.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}